Holen Sie sich die Stockscreener-App
0.7476
9.72%
-0.073
Schlusskurs vom Vortag:
$0.8206
Offen:
$0.83
24-Stunden-Volumen:
1.80M
Relative Volume:
3.72
Marktkapitalisierung:
$54.68M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-86.08M
KGV:
-0.2909
EPS:
-2.57
Netto-Cashflow:
$-72.06M
1W Leistung:
-16.76%
1M Leistung:
-37.75%
6M Leistung:
-44.51%
1J Leistung:
-26.65%
1-Tages-Spanne:
$0.73
$0.8603
1-Wochen-Bereich:
$0.73
$0.9799
52-Wochen-Spanne:
$0.73
$2.098
Io Biotech Inc Stock (IOBT) Company Profile
Firmenname
Io Biotech Inc
Sektor
Branche
Telefon
(457) 070-2980
Adresse
OLE MAALOES VEH 3, COPENHAGEN
Vergleichen Sie IOBT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| IOBT | 0.7402 | 54.68M | 0 | -86.08M | -72.06M | -2.57 |
| VRTX | 450.45 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.45 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.18 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.61 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.90 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Io Biotech Inc Aktie (IOBT) Neueste Nachrichten
U.S. shares lower at close of trade; Dow Jones Industrial Average down 1.51% - MSN
HC Wainwright Decreases Earnings Estimates for IO Biotech - MarketBeat
Neuronetics (NASDAQ: STIM) Announces Key Financial Updates and FDA Clearance for Adolescent Treatment - Defense World
Academy Sports and Outdoors, Inc. (NASDAQ:ASO) Receives $62.50 Average Price Target from Analysts - Defense World
IO Biotech (NASDAQ:IOBT) Given "Buy" Rating at HC Wainwright - MarketBeat
IO Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences - The Manila Times
IO Biotech Reports Advancing Cancer Trials Despite Widening Q3 Losses; Cash Position at $80.2M | IOBT Stock News - StockTitan
IO Biotech Announces Participation in Upcoming Investor Conferences - Marketscreener.com
IO Biotech to Present at Jefferies, Piper Sandler Healthcare Conferences | IOBT Stock News - StockTitan
Asia stocks fall as China stimulus disappoints, deflation persists - Investing.com
IO Biotech, Inc. Announces Data from the NSCLC Cohort in the Phase 2 Basket Trial of IO102-IO103 - Marketscreener.com
Promising results for IO Biotech’s cancer vaccine By Investing.com - Investing.com Canada
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study - ForexTV.com
IO Biotech's Cancer Vaccine Shows 81% Disease Control Rate in Lung Cancer Trial | IOBT Stock News - StockTitan
Here's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Situation - Yahoo Finance
Legend Biotech Chooses Philadelphia for New R&D Center - BioBuzz
Short Interest in IO Biotech, Inc. (NASDAQ:IOBT) Declines By 12.7% - MarketBeat
Melanoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
IO Biotech, Inc. (NASDAQ:IOBT) Shares Sold by Novo Holdings A S - MarketBeat
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
Non-melanoma Skin Cancer is Predicted to Exhibit Remarkable - GlobeNewswire
Melanoma Clinical Trials 2024: EMA, PDMA, FDA Approvals, - openPR
Melanoma Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA, Companies by DelveInsight - Barchart
38,076 Shares in Montauk Renewables, Inc. (NASDAQ:MNTK) Bought by Squarepoint Ops LLC - Defense World
Bank of America Boosts Voya Financial (NYSE:VOYA) Price Target to $88.00 - Defense World
IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Update - MarketBeat
Norstella introduces a fully integrated data asset for biopharma - European Pharmaceutical Manufacturer
Immuno-Oncology Clinical Trials Market Valuation to Reach $18.1 Billion By 2032 - 대구포스트
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting - ForexTV.com
VerImmune Secures $4.5 Million to Drive Biotech Innovation - BioBuzz
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting - The Manila Times
ARHT Media Inc. Announces Filing for Bankruptcy - The Manila Times
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's 39th Annual Meeting - Marketscreener.com
United States shares lower at close of trade; Dow Jones Industrial Average down 1.51% - MSN
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.51% - MSN
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
5 Best Stem Cell Companies to Invest In (November 2024) - Securities.io
ProShare Advisors LLC Sells 113 Shares of Reinsurance Group of America, Incorporated (NYSE:RGA) - Defense World
Novo Holdings A S Sells 658,809 Shares of IO Biotech, Inc. (NASDAQ:IOBT) - MarketBeat
American Century Companies Inc. Purchases 75,475 Shares of Lifetime Brands, Inc. (NASDAQ:LCUT) - Defense World
PCI Pharma Services invests over $365 million in EU and US facilities - European Pharmaceutical Manufacturer
Sei Investments Co. Buys 24,363 Shares of IQVIA Holdings Inc. (NYSE:IQV) - Defense World
Cancer Vaccines Market Detailed In Recent Development to Grow - openPR
Up 41% YTD, This Standout Growth Stock Has More Upside Ahead - The Globe and Mail
Investors in cash trouble should check out IO Biotech Inc (IOBT) - SETE News
Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket - Benzinga
IO Biotech (NASDAQ:IOBT) Rating Reiterated by HC Wainwright - Defense World
IO Biotech (NASDAQ:IOBT) PT Raised to $6.00 - Defense World
IO Biotech Inc [IOBT] moved up 3.22: Why It’s Important - The DBT News
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Finanzdaten der Io Biotech Inc-Aktie (IOBT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):